Medipost Co Ltd
KOSDAQ:078160
Medipost Co Ltd
Research & Development
Medipost Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Medipost Co Ltd
KOSDAQ:078160
|
Research & Development
-₩68.8B
|
CAGR 3-Years
-62%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
-41%
|
|
|
S
|
Seouleaguer Co Ltd
KOSDAQ:043710
|
Research & Development
-₩1.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
43%
|
|
Medipost Co Ltd
Glance View
Medipost Co., Ltd. engages in the development and manufacture of stem cell biotechnology products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2005-07-29. The firm mainly operates cord blood banks. Its cord blood banks consist of public cord blood bank, which provides resource to anyone who may need to undergo hematopoietic stem cell transplantation (HSCT) as a result of blood-related diseases, such as leukemia or aplastic anemia, as well as family cord blood bank, which provides services for storing newborn’s cord blood exclusively for family’s use. The company also involves in the provision of stem cell drugs, which are used for recovery of knee articular cartilage and others, distribution of healthcare food and natural cosmetics, as well as provision of healthcare services.
See Also
What is Medipost Co Ltd's Research & Development?
Research & Development
-68.8B
KRW
Based on the financial report for Sep 30, 2025, Medipost Co Ltd's Research & Development amounts to -68.8B KRW.
What is Medipost Co Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-41%
Over the last year, the Research & Development growth was -59%. The average annual Research & Development growth rates for Medipost Co Ltd have been -62% over the past three years , -49% over the past five years , and -41% over the past ten years .
